Expertise in
15
conditions

Dr. John C. Krauss

Oncology | Hematology
7500 Challis Rd, Entrance1, Level 1, 
Brighton, MI 
Accepting New Patients
Expertise in
15
conditions
7500 Challis Rd, Entrance1, Level 1, 
Brighton, MI 

Overview

John C. Krauss, M.D., graduated from the University of Michigan Medical School in 1985, did his Internal Medicine training at the University of Minnesota, and then returned to the University of Michigan for his Hematology and Oncology specialty training. Dr. Krauss joined the University of Michigan Faculty in 1992, and then moved his research lab to the Cleveland Clinic to continue clinical research on harnessing the immune system to combat cancer. In 1998, Dr. Krauss came back to Ann Arbor to be the Associate Director of the Ann Arbor Community Cancer Oncology Program at St. Joseph Mercy Hospital, and rose through the ranks to be the Section Head of Hematology/Oncology. Dr. Krauss treats a wide variety of patients with cancer, including breast cancer, colon cancer, lung cancer, and kidney cancer, focusing both on providing the highest possible cure rates for cancer and the best quality of life for the patient while on the journey.

Dr. Krauss is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Squamous Cell Carcinoma of the Anal Canal (SCAC).

Dr. Krauss is board certified in Internal Medicine and Medical Oncology. He is actively involved in clinical research, co-authoring 62 peer reviewed articles and participating in 11 clinical trials. Dr. Krauss is currently accepting new patients.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in MI

Board Certifications

Internal Medicine
Medical Oncology

Fellowships

University of Michigan Health System, Internal Medicine Hematology Oncology, 1992

Hospital Affiliations

University Of Michigan Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Brighton Center for Specialty Care
7500 Challis Rd, Entrance1, Level 1, Brighton, MI 48116
Other Locations
Multidisciplinary Colorectal Cancer Clinic
1500 E Medical Center Dr, Level B1 Reception E, Ann Arbor, MI 48109

Additional Areas of Focus

Dr. Krauss has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Colorectal Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 01, 2026
Intervention Type: Drug
Study Drugs: Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Study Phase: Phase 1
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 23, 2024
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase 1b Study of OMP-305B83 Plus FOLFIRI or FOLFOX as Second Line Therapy in Subjects With Metastatic Colorectal Cancer
A Phase 1b Study of OMP-305B83 Plus FOLFIRI or FOLFOX as Second Line Therapy in Subjects With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

62 Total Publications

The Impact of Side Effects on Oral Anticancer Agent Self-Management: Patient Perception of Risks Matters.
The Impact of Side Effects on Oral Anticancer Agent Self-Management: Patient Perception of Risks Matters.
Journal: Oncology nursing forum
Published: June 24, 2026
Similar Doctors
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine
Referral may be required

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception E, 
Ann Arbor, MI 
 (18.4 miles away)
734-647-8902
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rashmi Chugh is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma. Dr. Chugh is currently accepting new patients.

Expertise in
36
conditions
Dr. Rajen J. Mody
Hematology | Oncology
Expertise in
36
conditions
Dr. Rajen J. Mody
Hematology | Oncology
Referral may be required

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (18.4 miles away)
734-936-9814
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Rajen Mody is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Mody is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Neuroepithelioma, and Bone Marrow Aspiration. Dr. Mody is currently accepting new patients.

Expertise in
33
conditions
Dr. Francis P. Worden
Hematology | Oncology | Pediatrics
Expertise in
33
conditions
Dr. Francis P. Worden
Hematology | Oncology | Pediatrics
Referral may be required

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception A, 
Ann Arbor, MI 
 (18.4 miles away)
734-647-8902
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology. Dr. Worden is currently accepting new patients.

Frequently Asked Questions about Dr. John C. Krauss

How do I make an appointment with Dr. John C. Krauss?

You can book an appointment with Dr. John C. Krauss by calling their office at 734-647-8902. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John C. Krauss a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John C. Krauss is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John C. Krauss specialize in?

While Dr. John C. Krauss is a Oncology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. John C. Krauss participate in research or clinical trials?

Yes. Dr. John C. Krauss has published 62 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. John C. Krauss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John C. Krauss accept my insurance?

Dr. John C. Krauss accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 734-647-8902 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krauss's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 53 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile